Asset Details
Do you wish to reserve the book?
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Do you wish to request the book?
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
2016
Overview
In two 16-week, placebo-controlled trials enrolling adults with moderate-to-severe atopic dermatitis, dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, was effective in controlling the signs and symptoms of atopic dermatitis.
Atopic dermatitis is a chronic, relapsing inflammatory skin disease that is characterized by the up-regulation of type 2 immune responses (including those involving type 2 helper T cells),
1
,
2
an impaired skin barrier, and increased
Staphylococcus aureus
colonization.
3
,
4
In patients with moderate-to-severe atopic dermatitis, skin lesions can encompass a large body-surface area and are frequently accompanied by intense, persistent pruritus, which leads to sleep deprivation, symptoms of anxiety or depression, and a poor quality of life.
5
–
7
For patients with moderate-to-severe atopic dermatitis, topical therapies have limited efficacy, and systemic treatments are associated with substantial toxic effects. Thus, there . . .
Publisher
Massachusetts Medical Society
Subject
/ Anti-Inflammatory Agents - adverse effects
/ Anti-Inflammatory Agents - therapeutic use
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - therapeutic use
/ Anxiety
/ Dermatitis, Atopic - complications
/ Dermatitis, Atopic - drug therapy
/ Eczema
/ Female
/ Humans
/ Injections, Subcutaneous - adverse effects
/ Interleukin-13 - antagonists & inhibitors
/ Interleukin-4 - antagonists & inhibitors
/ Male
/ Nasopharyngitis - chemically induced
/ Patients
/ Pruritus
/ Skin
